DMI Biosciences, Inc.

Global Organoids Market to grow at a CAGR of ~14% by 2030, driven by personalized medicine, organoid use in drug discovery, and cancer research. North America leads the market, with key players including Thermofisher Scientific Inc., StemCell Technologies Inc., and others. Organoids mimic human organs, aiding in disease modeling and drug testing, but face challenges like high costs and limited vascularization.

Lack of funding and understanding of long COVID's mechanisms hinder drug development, frustrating patients and researchers. Despite initial positive results with Ampligen, Aim ImmunoTech faced funding challenges. The NIH's RECOVER initiative focuses on observational studies rather than new compounds, and private investors avoid long COVID due to perceived risk. Small biotech companies struggle to sustain research efforts, with some shifting focus or shutting down. Public-private partnerships and increased federal funding are suggested as solutions to advance long COVID treatment research.